Saroja Pharma Industries Approves Financial Results for FY 2026; Capital Structure and Performance Data Released
Saroja Pharma Industries India Limited announced that its Board of Directors held a meeting on May 30, 2026, where it approved the audited standalone financial results for the half year and the full financial year ended March 31, 2026. The board also received and noted the Independent Auditor's Report, which provided an unmodified opinion on the financial results.Following the approval of the financial results, the company announced that the trading window for insider securities transactions would open after 48 hours from the declaration of the financial results.
Financial Performance Review
The company's financial statements, including the Balance Sheet, Statement of Profit and Loss, and Cash Flow Statement, reveal significant operational movements between March 31, 2025, and March 31, 2026.Balance Sheet Highlights (Rupees in Lakhs)
| Particulars | As at 31.03.2026 | As at 31.03.2025 |
|---|---|---|
| EQUITY AND LIABILITIES TOTAL | 4,174.67 | 3,955.27 |
| Shareholders' Funds (Share Capital) | 402.05 | 402.05 |
| Shareholders' Funds (Reserves and Surplus) | 1,326.96 | 1,165.52 |
| Non-Current Liabilities (Long-term Borrowings) | 736.05 | 138.08 |
| Current Liabilities (Trade Payables) | 846.50 | 1,364.88 |
| ASSETS TOTAL | 4,174.67 | 3,955.27 |
| Property, Plant & Equipment | 218.03 | 250.66 |
| Property, Plant & Equipment (Capital Work-in-progress) | 2,033.68 | 861.25 |
| Current Assets (Inventories) | 85.98 | 9.85 |
| Current Assets (Trade Receivables) | 1,730.31 | 2,657.83 |
Profit and Loss Statement (Rupees in Lakhs)
The Profit and Loss statement for the year ended March 31, 2026, showed a Net Profit before tax of 223.29, compared to 144.92 for the previous year.
| Particulars | 6 Months Ended 31.03.2026 (Audited) | 6 Months Ended 31.03.2025 (Audited) | Year ended 31.03.2026 (Audited) | Year ended 31.03.2025 (Audited) |
|---|---|---|---|---|
| Net Sales / Income From Operations | 3,176.92 | 3,835.98 | 7,012.90 | 5,372.68 |
| Total Income from Operations (Net) | 3,147.40 | 3,876.41 | 7,023.81 | 5,391.20 |
| Cost of material consumed | 2,745.33 | 3,713.31 | 6,458.64 | 4,827.78 |
| Total Expenses | 3,001.88 | 3,798.13 | 6,800.01 | 5,246.28 |
| Profit before Tax | 145.51 | 78.28 | 223.79 | 144.92 |
| Net Profit for the Period From Continuing Operations | 104.46 | 56.98 | 161.80 | 103.42 |
Cash Flow Statement Analysis
The cash flow data illustrates the company's cash generation and utilization across various activities for the year ended March 31, 2026, versus 2025.
| Activity | For the Year ended 31.03.2026 (Amount in Lakhs) | For the Year ended 31.03.2025 (Amount in Lakhs) |
|---|---|---|
| Net cash generated/ (used in) from operating activities | 744.06 | 114.83 |
| Net Cash used in Investing Activities | -1,167.97 | -270.06 |
| Net Cash used in Financing Activities | 424.56 | 156.26 |
| Net Increase/(Decrease) in Cash and Cash Equivalents | 00.66 | 01.02 |
| Cash and Cash Equivalents at the end of the year | 33.87 | 33.21 |
IPO Proceeds Utilization
The company provided details regarding the utilization of proceeds from its Initial Public Offering (IPO) as of March 31, 2026. The total amount allotted for these objectives was 911.23.| Object Of the Issue | Amount Alloted For Project | Amount utilized till 31 March 2026 | Amount unutilized till 31 March 2026 |
|---|---|---|---|
| To Set - up a Manufacturing Unit | 704.88 | 704.88 | 0 |
| To Repay the Unsecured Loan of the Company | 175.00 | 175.00 | 0 |
| Public Issue Expenses | 31.35 | 31.35 | 0 |
| Total | 911.23 | 911.23 | 0 |
SAROJA Stock Price Movement
On Friday, Saroja Pharma Industries India Limited shares settled at ₹32.50, posting a marginal 0.00% change for the session. The stock saw activity on a trading volume of 1,600 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: